Industry’s run of raising enormous amounts of cash for new and growing biopharmaceutical companies has created a double-edged sword, producing a shortage of talent to run these firms and to oversee research and development pipelines fueled by record-breaking levels of venture capital investment and initial public offerings.
Biopharma’s talent crisis has been impacted by COVID-19 in important ways as well. Companies had to rapidly hire additional employees...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
